Allspring Global Investments Holdings LLC Reduces Position in Novartis AG $NVS

Allspring Global Investments Holdings LLC decreased its holdings in shares of Novartis AG (NYSE:NVS) by 3.2% during the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 102,595 shares of the company’s stock after selling 3,445 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Novartis were worth $15,911,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Independent Financial Group LLC purchased a new stake in shares of Novartis during the first quarter valued at $642,000. Prosperity Consulting Group LLC grew its holdings in shares of Novartis by 65.2% in the first quarter. Prosperity Consulting Group LLC now owns 2,833 shares of the company’s stock worth $433,000 after purchasing an additional 1,118 shares during the last quarter. Smart Money Group LLC increased its stake in Novartis by 8.0% in the 1st quarter. Smart Money Group LLC now owns 10,591 shares of the company’s stock worth $1,618,000 after buying an additional 780 shares during the period. Noesis Capital Mangement Corp bought a new stake in Novartis during the 1st quarter valued at about $208,000. Finally, Bank of New York Mellon Corp lifted its holdings in Novartis by 3.0% during the 1st quarter. Bank of New York Mellon Corp now owns 327,817 shares of the company’s stock valued at $50,074,000 after buying an additional 9,691 shares in the last quarter. 13.12% of the stock is currently owned by hedge funds and other institutional investors.

More Novartis News

Here are the key news stories impacting Novartis this week:

• Positive Sentiment: Novartis topped Q2 earnings estimates, posting $2.41 per share versus $2.17 expected, while revenue also came in above forecasts. The beat was driven by strong demand for key drugs and lower-than-expected costs. Novartis earnings report
• Positive Sentiment: The company returned to sales growth in Q2 as newer medicines offset generic pressure, with strength in cancer and multiple sclerosis treatments helping support results. Reuters Q2 profit story
• Positive Sentiment: Management reaffirmed full-year 2026 guidance, which suggests confidence that growth from newer products can continue despite headwinds. Zacks earnings recap
• Neutral Sentiment: Investors are also watching upcoming late-stage trial readouts in the second half of the year, which could influence the stock’s longer-term valuation narrative. Reuters pipeline valuation story
• Negative Sentiment: Ongoing generic competition and a sharp drop in Entresto sales remain major headwinds, and investors may worry about pressure on older blockbusters. Invezz Entresto sales drop story

Novartis Stock Up 2.8%

Shares of Novartis stock opened at $153.82 on Wednesday. The company has a debt-to-equity ratio of 0.96, a current ratio of 0.85 and a quick ratio of 0.65. Novartis AG has a 1 year low of $112.34 and a 1 year high of $170.46. The firm’s 50-day moving average is $151.61 and its two-hundred day moving average is $151.88. The stock has a market cap of $293.51 billion, a price-to-earnings ratio of 22.04, a PEG ratio of 2.58 and a beta of 0.45.

Novartis (NYSE:NVS) last posted its quarterly earnings results on Tuesday, June 30th. The company reported $2.41 EPS for the quarter. Novartis had a net margin of 24.87% and a return on equity of 38.82%. The business had revenue of $14.95 billion during the quarter. As a group, research analysts expect that Novartis AG will post 8.75 earnings per share for the current fiscal year.

Analyst Ratings Changes

NVS has been the topic of a number of research analyst reports. Morgan Stanley upped their target price on shares of Novartis from $143.00 to $170.00 and gave the stock an “overweight” rating in a research note on Thursday, March 26th. Weiss Ratings downgraded shares of Novartis from a “buy (a-)” rating to a “buy (b)” rating in a research note on Wednesday, April 29th. Seven research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $141.20.

Novartis Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.